Autoinjectors Market Size to grow by USD 303655.4 million between 2024-2028
According to a research report “ Autoinjectors Market” by Application (Anaphylaxis, Multiple sclerosis, Rheumatoid arthritis, Diabetes) End-user (Hospitals and clinics, Self-administration) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 303655.4 million, at a CAGR of over 36.72% during the forecast period. In the global health landscape, food, pollen, additives, latex, and dust allergies are on the rise, with anaphylaxis being a severe consequence. The Centers for Disease Control and Prevention (CDC) in the US identifies allergies as a leading chronic illness, incurring over USD18 billion in annual expenditures. Approximately 50 million North Americans and 30-35% of the global population grapple with allergies yearly. Anaphylaxis, a life-threatening allergic reaction, necessitates immediate intervention, often involving epinephrine autoinjectors.
Browse market data tables, figures, and in-depth TOC on “Autoinjectors Market” by Application (Anaphylaxis, Multiple sclerosis, Rheumatoid arthritis, Diabetes) End-user (Hospitals and clinics, Self-administration) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Application, the Anaphylaxis segment is projected to dominate the market size in 2024
In the healthcare sector of developed nations, autoinjectors hold significant value, primarily in outpatient and emergency units of high-end hospitals and clinics. These facilities prioritize their use for insured patients, managing their inventory through unit stocks or automated dispensing cabinets. Autoinjectors are indispensable for treating various medical conditions, often serving as the initial line of treatment drugs. The National Comprehensive Cancer Network (NCCN) advocates for the utilization of epinephrine autoinjectors in anaphylaxis cases, addressing concerns over potential errors in dose calculations and incorrect administration routes from traditional epinephrine ampules or vials.
By End-user, Hospitals and clinics segment is expected to hold the largest market size for the year 2024
The anaphylaxis segment dominates the autoinjectors market due to the escalating prevalence of anaphylaxis and food allergies worldwide. For instance, approximately 8% of children in the US alone are diagnosed with food allergies. Anaphylaxis, a life-threatening condition, necessitates immediate treatment, primarily through intramuscular epinephrine administration. The US epinephrine market is projected to expand significantly during the forecast period, driven by the high adoption rate of generic epinephrine autoinjectors among patients.
North America is forecasted to hold the largest market size by region in 2024
The autoinjector market witnesses significant growth due to the increasing prevalence of chronic diseases and the rising demand for self-administered medications. Key players in this industry focus on innovation and technological advancements to improve patient experience and ensure accurate dosage delivery. Additionally, regulatory approvals and collaborations drive market expansion.
The Autoinjectors Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
In the healthcare sector, the autoinjector market holds significant importance, particularly in managing emergency conditions such as anaphylactic shocks caused by food allergens or biologics. These devices enable self-administration of essential medications like Epinephrine, a critical drug in treating anaphylaxis. Pharmaceutical industries manufacture various types of autoinjectors, including syringes and pens, such as EpiPen autoinjectors. Healthcare providers play a crucial role in ensuring patients with chronic disorders, including needle phobia, have access to these life-saving devices. Autoinjectors offer needle-free alternatives, making drug delivery more convenient and less intimidating for patients. Anaphylaxis, a severe allergic reaction, can be fatal if not treated promptly. Epinephrine autoinjectors are essential in such emergency situations. The autoinjector market faces challenges like loss of exclusivity due to increasing competition and generic alternatives. However, the growing awareness of anaphylaxis and the need for quick and effective treatment continue to drive market growth. In summary, the autoinjector market plays a vital role in delivering essential medications during critical healthcare situations, ensuring patient safety and well-being.
Market Research Overview
In the healthcare sector, the autoinjector market holds significant importance, particularly for patients managing chronic inflammatory disorders such as asthma, hypertension, Multiple Sclerosis, and hormone deficiencies. These devices, available as autoinjector syringes, pens, or needle-free injectors, ensure safety and accuracy in drug administration. They come equipped with features like automatic drug reconstitution, safety locks, dosage recording, Bluetooth connectivity, and audio-visual cues. Autoinjectors play a crucial role in emergency situations, such as anaphylactic shocks, by delivering essential medications like Epinephrine quickly and effectively. Pharmaceutical industries and healthcare providers collaborate to develop these devices for various conditions, including anaphylaxis caused by food allergens. Spring-powered autoinjectors offer speed and convenience, while needle-phobic patients benefit from needle-free injectors. The autoinjector market is expanding, with advancements in medical technology leading to innovations like biologics and loss of exclusivity for certain autoinjector brands. These developments contribute to the growing demand for autoinjectors in home care settings. Overall, the autoinjector market is a vital component of the healthcare industry, ensuring safety, efficiency, and convenience for patients managing chronic conditions.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
